Solid Biosciences Files 2024 10-K, Details Gene Therapy Progress
Ticker: SLDB · Form: 10-K · Filed: Mar 6, 2025 · CIK: 1707502
| Field | Detail |
|---|---|
| Company | Solid Biosciences Inc. (SLDB) |
| Form Type | 10-K |
| Filed Date | Mar 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, gene therapy, biotechnology, R&D
TL;DR
Solid Bio's 2024 10-K shows continued R&D investment in gene therapy, with cash runway supporting milestones. Feb 2025 offering noted.
AI Summary
Solid Biosciences Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its progress in developing gene therapies. The company highlighted its ongoing clinical trials and research efforts, with a focus on Duchenne muscular dystrophy. Financials indicate continued investment in research and development, with cash reserves supporting operations through anticipated milestones. The filing also disclosed a subsequent event related to a February 2025 offering.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Solid Biosciences' financial health, operational progress, and strategic direction in the competitive gene therapy market.
Risk Assessment
Risk Level: medium — Biotechnology companies like Solid Biosciences face inherent risks related to clinical trial success, regulatory approvals, and market adoption of novel therapies.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-02-19 — Offering Date (Date of the February 2025 subsequent event offering)
Key Players & Entities
- Solid Biosciences Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- February 2025 Offering (event) — Subsequent event disclosed
- Duchenne muscular dystrophy (disease) — Focus of gene therapy development
- Charlestown, MA (location) — Company headquarters
FAQ
What is the primary focus of Solid Biosciences' gene therapy development as detailed in the 2024 10-K?
The 10-K filing indicates a primary focus on developing gene therapies for Duchenne muscular dystrophy.
What significant subsequent event did Solid Biosciences report in its 2024 10-K?
Solid Biosciences reported a subsequent event related to an offering that occurred on February 19, 2025.
When did the fiscal year covered by this 10-K filing end?
The fiscal year covered by this 10-K filing ended on December 31, 2024.
Where is Solid Biosciences Inc. headquartered?
Solid Biosciences Inc. is headquartered in Charlestown, MA.
What is the SIC code for Solid Biosciences Inc.?
The Standard Industrial Classification (SIC) code for Solid Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 6, 2025 regarding Solid Biosciences Inc. (SLDB).